6 completed, 2 active not recruiting, 2 recruiting, 1 terminated. 7 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 3, Active not recruiting 2, Recruiting 2 |
| Phase 2 | 6 | Completed 3, Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow Qurient Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease Adrixetinib - Chronic Graft-Versus-Host Disease | Phase 1 | Recruiting | Qurient Co., Ltd. | 18 | 2025-12-23 | 2025-12-30 |
| Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Venetoclax, Q702 - Acute Myeloid Leukemia | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 17 | 2025-02-12 | 2026-05-29 |
| Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors Q702, Pembrolizumab - Esophageal Cancer, Gastric Cancer | Phase 1 / Phase 2 | Active not recruiting | Qurient Co., Ltd. | 120 | 2023-01-12 | 2026-02-24 |
| Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors Q901, KEYTRUDA® (pembrolizumab) - Advanced Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | Qurient Co., Ltd. | 130 | 2022-08-30 | 2025-08-17 |
| A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients Telacebec, COVID-19 Standard of care - COVID-19 Virus Infection | Phase 2 | Terminated | Qurient Co., Ltd. | 1 | 2021-07-29 | 2022-03-02 |
| Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor Q702 - Solid Tumor, Advanced Cancer | Phase 1 | Completed | Qurient Co., Ltd. | 51 | 2020-11-18 | 2025-12-30 |
| A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203) Telacebec (Q203), Rifafour e-275 - Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB | Phase 2 | Completed | Qurient Co., Ltd. | 60 | 2018-07-23 | 2019-09-10 |
| Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients Q301 Cream, Vehicle - Atopic Dermatitis | Phase 2 | Completed | Qurient Co., Ltd. | 258 | 2018-06-21 | 2020-04-24 |
| A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers Q203, Placebo - Healthy Volunteers | Phase 1 | Completed | Qurient Co., Ltd. | 47 | 2016-08-01 | 2018-05-14 |
| A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers Q203, Placebo - Healthy Volunteers | Phase 1 | Completed | Qurient Co., Ltd. | 56 | 2015-08-01 | 2016-12-06 |
| Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients Q301 Cream, Placebo - Moderate to Severe Atopic Dermatitis | Phase 2 | Completed | Qurient Co., Ltd. | 57 | 2015-04-01 | 2016-12-06 |
Neoplasm Metastasis (2) · Bronchiolitis Obliterans Syndrome (1) · COVID-19 (1) · Dermatitis, Atopic (1) · Esophageal Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Liver Neoplasms (1) · Stomach Neoplasms (1) · Uterine Cervical Neoplasms (1)
telacebec (4) · pembrolizumab (2) · Azacitidine (1) · venetoclax (1)
United States (8) · South Africa (2) · South Korea (2) · Spain (1)